U.S. AI In Oncology Market Size $7,710.88 Million By 2032, CAGR: 27.1%

U.S. AI In Oncology Market Size Worth $7,710.88 Million By 2032 | CAGR: 27.1%

The U.S. AI In oncology market size is expected to reach USD 7,710.88 million by 2032, according to a new study by Polaris Market Research. The report U.S. AI In Oncology Market Share, Size, Trends, Industry Analysis Report, By Component (Software Solutions, Hardware, Services); By Cancer Type; By Application; By End-Use; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The AI in oncology in the United States is driven by several factors, including the need for more precise and personalized cancer treatments, the growing volume of medical data, and the desire to improve patient outcomes and reduce healthcare costs. As cancer diagnosis and treatment become increasingly complex, AI technologies offer opportunities to revolutionize oncology practice and contribute to driving the market in the US.

In the US market, AI is spearheading a revolutionary transformation in the field of oncology by harnessing extensive datasets derived from multi-omics analyses, complemented by advancements in deep learning and high-performance computing. This seamless integration of AI technology into oncology is revolutionizing various facets of cancer management, spanning from detection and screening to diagnosis and classification.

AI plays a pivotal role in deciphering cancer genomics, scrutinizing the intricacies of the tumor microenvironment, evaluating prognostic and predictive biomarkers, and devising tailored strategies for post-diagnostic care and drug discovery. By deploying AI algorithms across these critical domains, healthcare practitioners are empowered to make more precise and informed decisions, ultimately enhancing the effectiveness and efficiency of cancer research and treatment. The comprehensive application of AI in oncology represents a significant leap forward in our ability to combat cancer, offering unprecedented insights and capabilities that hold immense promise for improving patient outcomes and advancing the frontier of oncological science in the United States.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/us-ai-in-oncology-market/request-for-sample

Technological advancements are driving substantial growth potential, especially in sectors prioritizing precision, safety, and automation. Within this dynamic environment, artificial intelligence (AI) emerges as a transformative force, poised to revolutionize oncology screening practices. With its unparalleled ability to analyze vast amounts of data with exceptional accuracy and speed, AI holds the promise of significantly improving screening rates in oncology. By leveraging sophisticated algorithms and machine learning techniques, AI can detect subtle patterns and anomalies indicative of cancerous growths at earlier stages than traditional methods, thereby enhancing the effectiveness of screening programs.

Recognizing the transformative potential of AI in oncology, both public and private entities are intensifying their focus on investing in research and development (R&D) initiatives aimed at advancing AI-based screening products. These investments span a wide spectrum, encompassing the refinement of AI algorithms, the development of innovative imaging technologies, and the creation of integrated diagnostic platforms that seamlessly integrate AI into clinical workflows.

U.S. AI In Oncology Market Report Highlights

  • In 2023, the breast cancer segment accounted for the largest market share in U.S. A.I. in the oncology market. The increasing incidence of breast cancer among individuals has spurred a heightened demand for technologically advanced products within the market.
  • In 2023, the chemotherapy segment accounted for the largest market share due to its established status, broad applicability, clinical experience, continued innovation, and integration with A.I. technologies in the United States.
  • The key market players In the U.S. market are ConcertAI, Azra A.I., Digital Diagnostics Inc., IBM, G.E. HealthCare, Intel Corporation, NVIDIA Corporation, PathAI, and more.

Polaris Market Research has segmented the U.S. AI in oncology market report based on component, cancer type, treatment type.

U.S. AI In Oncology, Component Outlook (Revenue - USD Million, 2019 - 2032)

  • Software Solutions
  • Hardware
  • Services

U.S. AI In Oncology, Cancer Type Outlook (Revenue - USD Million, 2019 - 2032)

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Brain Tumor
  • Others

U.S. AI In Oncology, Treatment Type Outlook (Revenue - USD Million, 2019 - 2032)

  • Chemotherapy
  • Radiotherapy
  • Immunotherapy
  • Others

U.S. AI In Oncology Market Report Scope

Report Attributes


Market size value in 2024

USD 1,128.69 million

Revenue forecast in 2032

USD 7,710.88 million


27.1% from 2024 – 2032

Base year


Historical data

2019 – 2022

Forecast period

2024 – 2032

Quantitative units

Revenue in USD million and CAGR from 2024 to 2032

Segments covered

By Component, By Cancer Type, By Treatment Type,


Report customization as per your requirements with respect to countries, region and segmentation.

For Specific Research Requirements

Request for Customized Report